Muhsin Balaban1, Orkunt Ozkaptan2, Alkan Cubuk3, Ahmet Sahan2, Mustafa Duzenli4, Murat Tuncer4. 1. Urology Department, Biruni University School of Medicine, Istanbul, Turkey. 2. Urology Department, Kartal Training and Research Hospital, E-5 Karayolu Cevizli Mevki, Kartal/Istanbul, Turkey. 3. Urology Department, Kartal Training and Research Hospital, E-5 Karayolu Cevizli Mevki, Kartal/Istanbul, Turkey. alkancubuk@hotmail.com. 4. Nephrology Department, Biruni University School of Medicine, Istanbul, Turkey.
Abstract
BACKGROUND: To evaluate the outcome of endoscopic treatment for symptomatic vesicoureteral reflux (VUR) disease in renal transplantation patients and to determine the factors that were associated with the success rate of the treatment. METHODS: A total of 121 symptomatic VUR diseases diagnosed between 2014 and 2018 in 3560 renal transplant patients. The results of 49 VUR cases that presented with febrile urinary tract infection (UTI) and were hospitalized for antibiotic treatment were included in the study. Reflux was detected by voiding cystourethrogram and treatment was performed by endoscopic Deflux® injection. The result of endoscopic treatment was evaluated clinically by 3 months periods. RESULTS: The mean time between transplantation and endoscopic treatment was 59.6 (5-132) months, and the mean follow-up period after the endoscopic treatment was 14 (6-48) months, respectively. The success rate after the first injection was 59.1% (n = 29) and 67.3% (n = 33) after the second injection. One patient developed anuria, one patient febrile UTI and four patients developed minimal macroscopic hematuria after the procedure. CONCLUSIONS: Endoscopic treatment of symptomatic VUR in transplanted kidney is a safe and feasible procedure. The amount of bulking agent or duration between the transplantation and diagnosis of VUR does not have any impact on the success of the treatment. However, the younger age of the patients and the female gender seem to have a positive effect on the outcome of the procedure.
BACKGROUND: To evaluate the outcome of endoscopic treatment for symptomatic vesicoureteral reflux (VUR) disease in renal transplantationpatients and to determine the factors that were associated with the success rate of the treatment. METHODS: A total of 121 symptomatic VUR diseases diagnosed between 2014 and 2018 in 3560 renal transplant patients. The results of 49 VUR cases that presented with febrile urinary tract infection (UTI) and were hospitalized for antibiotic treatment were included in the study. Reflux was detected by voiding cystourethrogram and treatment was performed by endoscopic Deflux® injection. The result of endoscopic treatment was evaluated clinically by 3 months periods. RESULTS: The mean time between transplantation and endoscopic treatment was 59.6 (5-132) months, and the mean follow-up period after the endoscopic treatment was 14 (6-48) months, respectively. The success rate after the first injection was 59.1% (n = 29) and 67.3% (n = 33) after the second injection. One patient developed anuria, one patient febrile UTI and four patients developed minimal macroscopic hematuria after the procedure. CONCLUSIONS: Endoscopic treatment of symptomatic VUR in transplanted kidney is a safe and feasible procedure. The amount of bulking agent or duration between the transplantation and diagnosis of VUR does not have any impact on the success of the treatment. However, the younger age of the patients and the female gender seem to have a positive effect on the outcome of the procedure.
Authors: Renate Pichler; Alexander Buttazzoni; Peter Rehder; Georg Bartsch; Hannes Steiner; Josef Oswald Journal: BJU Int Date: 2010-11-08 Impact factor: 5.588
Authors: K Ohba; M Matsuo; M Noguchi; M Nishikido; S Koga; H Kanetake; A Nazneen; D Liu; M S Razzaque; T Taguchi Journal: Clin Transplant Date: 2004 Impact factor: 2.863